Wierzbicki AS, Poston R, Ferro A,. The lipid and non-lipid effects of statins. Pharmacol Ther 2003; 99 (1): 95-112.
Beri A, Sural N, Mahajan SB,. Non-atheroprotective effects of statins: a systematic review. Am J Cardiovasc Drugs 2009; 9 (6): 361-70.
Kor DJ,. Statins and acute lung injury: Holy Grail or the next to fail? Crit Care Med 2012; 40 (5): 1661-3.
Janda S, Young A, Fitzgerald JM, Etminan M, Swiston J,. The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis. J Crit Care 2010; 25 (4): 656-22.
Katsiki N, Wierzbicki AS, Mikhailidis DP,. Pulmonary arterial hypertension and statins: an update. Curr Opin Cardiol 2011; 26 (4): 322-6.
Young RP, Hopkins R, Eaton TE,. Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev 2009; 18 (114): 222-32.
Saad N, Camus P, Suissa S, Ernst P,. Statins and the risk of interstitial lung disease: a cohort study. Thorax 2013; 68 (4): 361-4.
Gowdy KM, Fessler MB,. Emerging roles for cholesterol and lipoproteins in lung disease. Pulm Pharmacol Ther 2013; 26 (4): 430-7.
Roszell BR, Tao JQ, Yu KJ, Huang S, Bates SR,. Characterization of the Niemann-Pick C pathway in alveolar type II cells and lamellar bodies of the lung. Am J Physiol Lung Cell Mol Physiol 2012; 302 (9): L919-32.
Meaney S, Bonfield TL, Hansson M, Babiker A, Kavuru MS, Thomassen MJ,. Serum cholestenoic acid as a potential marker of pulmonary cholesterol homeostasis: increased levels in patients with pulmonary alveolar proteinosis. J Lipid Res 2004; 45 (12): 2354-60.
Leonenko Z, Gill S, Baoukina S, et al. An elevated level of cholesterol impairs self-assembly of pulmonary surfactant into a functional film. Biophys J 2007; 93 (2): 674-83.
Wang W, Xu H, Shi Y, et al. Genetic deletion of apolipoprotein A-I increases airway hyperresponsiveness, inflammation, and collagen deposition in the lung. J Lipid Res 2010; 51 (9): 2560-70.
Massaro D, Massaro GD,. Apoetm1Unc mice have impaired alveologenesis, low lung function, and rapid loss of lung function. Am J Physiol Lung Cell Mol Physiol 2008; 294 (5): L991-7.
Bates SR, Tao JQ, Collins HL, Francone OL, Rothblat GH,. Pulmonary abnormalities due to ABCA1 deficiency in mice. Am J Physiol Lung Cell Mol Physiol 2005; 289 (6): L980-9.
Wojcik AJ, Skaflen MD, Srinivasan S, Hedrick CC,. A critical role for ABCG1 in macrophage inflammation and lung homeostasis. J Immunol 2008; 180 (6): 4273-82.
Pulfer MK, Murphy RC,. Formation of biologically active oxysterols during ozonolysis of cholesterol present in lung surfactant. J Biol Chem 2004; 279 (25): 26331-8.
Imai Y, Kuba K, Neely GG, et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 2008; 133 (2): 235-49.
Uhlig S, Gulbins E,. Sphingolipids in the lungs. Am J Respir Crit Care Med 2008; 178 (11): 1100-14.
Zhou Q, Gensch C, Liao JK,. Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol Sci 2011; 32 (3): 167-73.
Edmonds Y, Milstien S, Spiegel S,. Development of small-molecule inhibitors of sphingosine-1-phosphate signaling. Pharmacol Ther 2011; 132 (3): 352-60.
Barnes PJ,. Future treatments for chronic obstructive pulmonary disease and its comorbidities. Proc Am Thorac Soc 2008; 5 (8): 857-64.
Holdaas H, Fellstrom B, Cole E, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005; 5 (12): 2929-36.
McKay A, Leung BP, McInnes IB, Thomson NC, Liew FY,. A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol 2004; 172 (5): 2903-8.
Paumelle R, Blanquart C, Briand O, et al. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ Res 2006; 98 (3): 361-9.
Montero MT, Hernandez O, Suarez Y, et al. Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. Atherosclerosis 2000; 153 (2): 303-13.
Zeki AA, Franzi L, Last J, Kenyon NJ,. Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond. Am J Respir Crit Care Med 2009; 180 (8): 731-40.
Imamura M, Okunishi K, Ohtsu H, et al. Pravastatin attenuates allergic airway inflammation by suppressing antigen sensitisation, interleukin 17 production and antigen presentation in the lung. Thorax 2009; 64 (1): 44-9.
Schaafsma D, Dueck G, Ghavami S, et al. The mevalonate cascade as a target to suppress extracellular matrix synthesis by human airway smooth muscle. Am J Respir Cell Mol Biol 2011; 44 (3): 394-403.
Takeda N, Kondo M, Ito S, Ito Y, Shimokata K, Kume H,. Role of RhoA inactivation in reduced cell proliferation of human airway smooth muscle by simvastatin. Am J Respir Cell Mol Biol 2006; 35 (6): 722-9.
Ahmad T, Mabalirajan U, Sharma A, et al. Simvastatin improves epithelial dysfunction and airway hyperresponsiveness: from asymmetric dimethyl-arginine to asthma. Am J Respir Cell Mol Biol 2011; 44 (4): 531-9.
Huang CC, Chan WL, Chen YC, et al. Statin use in patients with asthma: a nationwide population-based study. Eur J Clin Invest 2011; 41 (5): 507-12.
Lokhandwala T, West-Strum D, Banahan BF, Bentley JP, Yang Y,. Do statins improve outcomes in patients with asthma on inhaled corticosteroid therapy? A retrospective cohort analysis BMJ Open 2012; 2 (3): pii: e001279.
Menzies D, Nair A, Meldrum KT, Fleming D, Barnes M, Lipworth BJ,. Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma. J Allergy Clin Immunol 2007; 119 (2): 328-35.
Hothersall EJ, Chaudhuri R, McSharry C, et al. Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma. Thorax 2008; 63 (12): 1070-5.
Fahimi F,. Do statins improve lung function in asthmatic patients? A randomized and double blind trial. Iranian J Pharm Sci 2009; 5 (1): 13-20.
Maneechotesuwan K, Ekjiratrakul W, Kasetsinsombat K, Wongkajornsilp A, Barnes PJ,. Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase. J Allergy Clin Immunol 2010; 126 (4): 754-62.
Zhao J, O'Donnell VB, Balzar S, St Croix CM, Trudeau JB, Wenzel SE,. 15-Lipoxygenase 1 interacts with phosphatidylethanolamine-binding protein to regulate MAPK signaling in human airway epithelial cells. Proc Natl Acad Sci U S A 2011; 108 (34): 14246-51.
Braganza G, Chaudhuri R, McSharry C, et al. Effects of short-term treatment with atorvastatin in smokers with asthma-a randomized controlled trial. BMC Pulm Med 2011; 11: 16.
Cowan DC, Cowan JO, Palmay R, Williamson A, Taylor DR,. Simvastatin in the treatment of asthma: lack of steroid-sparing effect. Thorax 2010; 65 (10): 891-6.
Silva D, Couto M, Delgado L, Moreira A,. A systematic review of statin efficacy in asthma. J Asthma 2012; 49 (9): 885-94.
Heart Protection Study Group. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Med 2005; 3: 6.
van Eeden SF, Sin DD,. Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease. Respiration 2008; 75 (2): 224-38.
Janda S, Park K, Fitzgerald JM, Etminan M, Swiston J,. Statins in COPD: a systematic review. Chest 2009; 136 (3): 734-43.
Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004; 110 (7): 880-5.
Frost FJ, Petersen H, Tollestrup K, Skipper B,. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007; 131 (4): 1006-12.
Wang MT, Lo YW, Tsai CL, et al. Statin use and risk of COPD exacerbation requiring hospitalization. Am J Med 2013; 126 (7): 598-606.
Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376 (9753): 1670-81.
Sheng X, Murphy MJ, Macdonald TM, et al. Effect of statins on total cholesterol concentrations, cardiovascular morbidity, and all-cause mortality in chronic obstructive pulmonary disease: a population-based cohort study. Clin Ther 2012; 34 (2): 374-84.
Alexeeff SE, Litonjua AA, Sparrow D, Vokonas PS, Schwartz J,. Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med 2007; 176 (8): 742-7.
Blamoun AI, Batty GN, DeBari VA, Rashid AO, Sheikh M, Khan MA,. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract 2008; 62 (9): 1373-8.
Dobler CC, Wong KK, Marks GB,. Associations between statins and COPD: a systematic review. BMC Pulm Med 2009; 9: 32.
Lee TM, Chen CC, Shen HN, Chang NC,. Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin Sci (Lond) 2009; 116 (6): 497-505.
Khan AR, Riaz M, Bin Abdulhak AA, et al. The role of statins in prevention and treatment of community acquired pneumonia: a systematic review and meta-analysis. PLoS ONE 2013; 8 (1): e52929.
Yamashita S, Tsubakio-Yamamoto K, Ohama T, Nakagawa-Toyama Y, Nishida M,. Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions. J Atheroscler Thromb 2010; 17 (5): 436-51.
Karnati S, Baumgart-Vogt E,. Peroxisomes in mouse and human lung: their involvement in pulmonary lipid metabolism. Histochem Cell Biol 2008; 130 (4): 719-40.
Ansquer JC, Foucher C, Aubonnet P, Le MK,. Fibrates and microvascular complications in diabetes-insight from the FIELD study. Curr Pharm Des 2009; 15 (5): 537-52.
Belvisi MG, Hele DJ,. Peroxisome proliferator-activated receptors as novel targets in lung disease. Chest 2008; 134 (1): 152-7.
Spears M, McSharry C, Thomson NC,. Peroxisome proliferator-activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease. Clin Exp Allergy 2006; 36 (12): 1494-504.
Kulkarni AA, Woeller CF, Thatcher TH, Ramon S, Phipps RP, Sime PJ,. Emerging PPARgamma-independent role of PPARgamma ligands in lung diseases. PPAR Res 2012; 2012: 705352.
Bauer CM, Zavitz CC, Botelho FM, et al. Treating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infection. PLoS ONE 2010; 5 (10): e13251.
Lakatos HF, Thatcher TH, Kottmann RM, Garcia TM, Phipps RP, Sime PJ,. The role of PPARs in lung fibrosis. PPAR Res 2007; 2007: 71323.
Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP,. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008; 23 (4): 370-8.
Sorci-Thomas MG, Thomas MJ,. High density lipoprotein biogenesis, cholesterol efflux, and immune cell function. Arterioscler Thromb Vasc Biol 2012; 32 (11): 2561-5.
Wierzbicki AS,. Lipoproteins: from A to B and maybe C-III. Int J Clin Pract 2008; 62 (5): 674-6.
Yao X, Remaley AT, Levine SJ,. New kids on the block: the emerging role of apolipoproteins in the pathogenesis and treatment of asthma. Chest 2011; 140 (4): 1048-54.
Wierzbicki AS,. Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. Curr Opin Cardiol 2009; 24 (4): 372-9.
Wierzbicki AS,. Niacin: the only vitamin that reduces cardiovascular events. Int J Clin Pract 2011; 65 (4): 379-85.
Kwon WY, Suh GJ, Kim KS, Kwak YH,. Niacin attenuates lung inflammation and improves survival during sepsis by downregulating the nuclear factor-kappaB pathway. Crit Care Med 2011; 39 (2): 328-34.
Popp L, Haussler A, Olliges A, et al. Comparison of nociceptive behavior in prostaglandin E, F, D, prostacyclin and thromboxane receptor knockout mice. Eur J Pain 2009; 13 (7): 691-703.
HPS2-THRIVE Investigators. A randomized trial of the long-term clinical effects of raising hdl cholesterol with extended release niacin/laropiprant. Heart protection study 2-treatment of HDL to reduce the incidence of vascular events (HPS2-THRIVE). ClinicalTrials.gov 2009 February 2NCT00461630. http://clinicaltrials.gov/ct2/show/NCT00461630 (accessed 1 June 2013).
van Eeden S, Leipsic J, Paul Man SF, Sin DD,. The relationship between lung inflammation and cardiovascular disease. Am J Respir Crit Care Med 2012; 186 (1): 11-6.
Man SF, van Eeden S, Sin DD,. Vascular risk in chronic obstructive pulmonary disease: role of inflammation and other mediators. Can J Cardiol 2012; 28 (6): 653-61.
Liosis S, Bauer T, Schiele R, et al. Predictors of 1-year mortality in patients with contemporary guideline-adherent therapy after acute myocardial infarction: results from the OMEGA study. Clin Res Cardiol 2013; 102 (9): 671-7.
Melbye H, Halvorsen DS, Hartz I, et al. Bronchial airflow limitation, smoking, body mass index, and statin use are strongly associated with the C-reactive protein level in the elderly. The Tromso Study 2001. Respir Med 2007; 101 (12): 2541-9.
Lawes CM, Thornley S, Young R, et al. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Prim Care Respir J 2012; 21 (1): 35-40.
Blanker MH, Bohnen AM, Groeneveld FP, et al. Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study. J Am Geriatr Soc 2001; 49 (4): 436-42.
Agarwal SK, Heiss G, Barr RG, et al. Airflow obstruction, lung function, and risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study. Eur J Heart Fail 2012; 14 (4): 414-22.
Wierzbicki AS,. New directions in cardiovascular risk assessment: the role of secondary risk stratification markers. Int J Clin Pract 2012; 66 (7): 622-30.
Barr RG, Ahmed FS, Carr JJ, et al. Subclinical atherosclerosis, airflow obstruction and emphysema: the MESA Lung Study. Eur Respir J 2012; 39 (4): 846-54.
Lahousse L, van den Bouwhuijsen Q, Loth DW, et al. Chronic obstructive pulmonary disease and lipid core carotid artery plaques in the elderly: the Rotterdam Study. Am J Respir Crit Care Med 2012; 187 (1): 58-64.
van Gestel YR, Hoeks SE, Sin DD, et al. COPD and cancer mortality: the influence of statins. Thorax 2009; 64 (11): 963-7.
Ishida W, Kajiwara T, Ishii M, et al. Decrease in mortality rate of chronic obstructive pulmonary disease (COPD) with statin use: a population-based analysis in Japan. Tohoku J Exp Med 2007; 212 (3): 265-73.
van Gestel YR, Hoeks SE, Sin DD, et al. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol 2008; 102 (2): 192-6.
Stone IS, Barnes NC, Petersen SE,. Chronic obstructive pulmonary disease: a modifiable risk factor for cardiovascular disease? Heart 2012; 98: 1055-62.
Stone IS, Petersen SE, Barnes NC,. Raised troponin in COPD: clinical implications and possible mechanisms. Heart 2013; 99 (2): 71-2.
Soyseth V, Bhatnagar R, Holmedahl NH, et al. Acute exacerbation of COPD is associated with fourfold elevation of cardiac troponin T. Heart 2013; 99 (2): 122-6.
Marcun R, Sustic A, Brguljan PM, et al. Cardiac biomarkers predict outcome after hospitalisation for an acute exacerbation of chronic obstructive pulmonary disease. Int J Cardiol 2012; 161 (3): 156-9.
Barker BL, Brightling CE,. Phenotyping the heterogeneity of chronic obstructive pulmonary disease. Clin Sci (Lond) 2013; 124 (6): 371-87.
McDonald VM, Higgins I, Wood LG, Gibson PG,. Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? Thorax 2013; 68 (7): 691-4.
Galban CJ, Han MK, Boes JL, et al. Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med 2012; 18 (11): 1711-5.
Stefan MS, Bannuru RR, Lessard D, Gore JM, Lindenauer PK, Goldberg RJ,. The impact of COPD on management and outcomes of patients hospitalized with acute myocardial infarction: a 10-year retrospective observational study. Chest 2012; 141 (6): 1441-8.
